Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE REGIMEN phase 3 trial

Chin Med J (Engl). 2024 Aug 20;137(16):1991-1992. doi: 10.1097/CM9.0000000000003159. Epub 2024 Jul 15.

¹ Department of Dermatology, Peking University First Hospital, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China.
² Department of Dermatology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.
³ Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China.
⁴ Department of Dermatology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China.
⁵ Department of Dermatology, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang 310014, China.
⁶ Pfizer S.A. de C.V., Mexico City, Mexico.
⁷ Pfizer Inc., New York, NY, USA.
⁸ Pfizer Investment Co., Ltd, Beijing 100010, China.
⁹ Pfizer (China) R&D Co., Ltd, Shanghai 201200, China.
¹⁰ Pfizer PBG, Shanghai 200041, China.

No abstract available

Publication types